By JOHN SAMARAS A US retail pharmacy pays $1,302 to acquire one month of branded Wegovy. That figure comes from the Centers for Medicare and Medicaid Services National Average Drug Acquisition Cost file, effective August 19, 2026, for the 25 mg oral tablet at 30 tablets a month. The cheapest cash price I verified on…
Jigar Shah, the company’s senior vice president and chief marketing and strategy officer, discusses impact of virtual care on utilization, cost and access
While SUD affects people across all demographics, a growing body of research and clinical experience makes one point clear: gender meaningfully influences how substance use develops, how it is experienced, and what supports effective treatment. The post Beyond One-Size-Fits-All: Women, Substance Use, and the Need for Gender-Responsive Care appeared first on MedCity News.
This brief describes the role of Medicaid Fraud Control Units (MFCUs) in program integrity efforts, examines caseload and case outcome data, and current issues facing MFCUs.
[Sponsored] Research from MedCity News and Cotiviti shows robust AI adoption by payers and providers, but what steps are they taking for AI governance and AI weaponized cybersecurity threats? The post Hospital and Payer AI Governance Is at a Crossroads appeared first on MedCity News.
The run-up to the midterm elections is turning into a food fight — literally. The summer was marred by a massive foodborne outbreak that sickened scores of people and the recall of tens of thousands of pounds of imported meat, turning the safety of the U.S. food supply into a topic of national conversation and…
Amye Joseph says America’s political polarization has made it an “interesting time” in her Tennessee household. She and her husband, Charlie, have been married 35 years. She’s a Republican. He’s a Democrat. But their shared disenchantment with profit-driven healthcare has provided a unifying target: pharmacy benefit managers, known as PBMs. The Josephs’ frustration is focused…
Audrey Mann Cronin takes over THCB today and has a THCB Gang special called “The Odyssey of Women’s Health: Journeying into the Midterms – Obstacles, Opportunities and What We Can Expect” The panel is Liz Powell, an attorney and Founder of both G2G Consulting and Women’s Health Advocates, and former Capitol Hill staffer; Dr. Elizabeth…
Mirum Pharmaceuticals’ Atebrioz is the third FDA-approved drug for fibrodysplasia ossificans progressiva (FOP), but it brings advantages over the two other products for this rare disease that leads to bone growth in soft tissue. Mirum acquired Atebrioz from Incyte earlier this year. The post Mirum Pharma Pill Lands FDA Approval for Ultra-Rare Bone Growth Disorder…
As AI technology in healthcare becomes more deeply involved in the complex, high-stakes tasks of diagnosis and treatment planning, traditional lines of accountability will become less clear. Where does the buck stop for AI-supported medical care? The post When AI Gets Medicine Wrong, Who’s Liable? appeared first on MedCity News.